ClinVar Miner

Submissions for variant NM_000051.4(ATM):c.4110-9C>G

dbSNP: rs730881367
Minimum review status: Collection method:
Minimum conflict level:
ClinVar version:
Total submissions: 7
Download table as spreadsheet
Submitter RCV SCV Clinical significance Condition Last evaluated Review status Method Comment
Labcorp Genetics (formerly Invitae), Labcorp RCV000474638 SCV000546867 uncertain significance Ataxia-telangiectasia syndrome 2023-04-18 criteria provided, single submitter clinical testing This sequence change falls in intron 27 of the ATM gene. It does not directly change the encoded amino acid sequence of the ATM protein. This variant is not present in population databases (gnomAD no frequency). In summary, the available evidence is currently insufficient to determine the role of this variant in disease. Therefore, it has been classified as a Variant of Uncertain Significance. Algorithms developed to predict the effect of sequence changes on RNA splicing suggest that this variant may disrupt the consensus splice site. ClinVar contains an entry for this variant (Variation ID: 407567). This variant has been observed in individual(s) with ataxia-telangiectasia (PMID: 21965147).
GeneDx RCV000479444 SCV000568321 likely pathogenic not provided 2022-12-06 criteria provided, single submitter clinical testing Not observed at significant frequency in large population cohorts (gnomAD); In silico analysis supports a deleterious effect on splicing; Non-canonical splice variant demonstrated to result in abnormal splicing (External communication with Ambry Genetics); This variant is associated with the following publications: (PMID: 21965147)
Ambry Genetics RCV001021891 SCV001183562 pathogenic Hereditary cancer-predisposing syndrome 2019-12-05 criteria provided, single submitter clinical testing The c.4110-9C>G intronic variant results from a C to G substitution 9 nucleotides upstream from coding exon 27 in the ATM gene. This alteration was identified along with a 2nd truncating mutation in a patient with a clinical diagnosis of ataxia telangiectasia (Demuth I et al. Neurogenetics, 2011 Nov;12:273-82). RNA analysis from lymphoblastoid cells established from the peripheral blood of this patient reveal that this variant activates a cryptic splice site resulting in an mRNA containing eight additional bases leading to a frame shift. This nucleotide position is poorly conserved in available vertebrate species. This alteration is predicted to decrease the efficiency of the native splice acceptor site by the BDGP and ESEfinder in silico models. RNA studies have demonstrated that this alteration results in abnormal splicing in the set of samples tested (Ambry internal data) resulting in an abnormal protein or a transcript that is subject to nonsense-mediated mRNA decay. As such, this alteration is classified as a disease-causing mutation.
Color Diagnostics, LLC DBA Color Health RCV001021891 SCV001360384 uncertain significance Hereditary cancer-predisposing syndrome 2023-02-09 criteria provided, single submitter clinical testing This variant causes a C>G nucleotide substitution at the -9 position of intron 27 of the ATM gene. The variant is predicted to damage the natural splice acceptor site and create a de novo acceptor site 8 basepairs upstream. Use of the de novo site would be expected to result in a frameshift at the protein level, but this has not been demonstrated experimentally. This variant has been reported to co-occur with ATM c.362T>A (p.Leu121*) in an individual affected with ataxia-telangiectasia in the literature, but the phase of the variants was not reported (PMID: 21965147). This variant has not been identified in the general population by the Genome Aggregation Database (gnomAD). The available evidence is insufficient to determine the role of this variant in disease conclusively. Therefore, this variant is classified as a Variant of Uncertain Significance.
Spanish ATM Cancer Susceptibility Variant Interpretation Working Group RCV001021891 SCV001911460 uncertain significance Hereditary cancer-predisposing syndrome 2020-06-17 criteria provided, single submitter clinical testing The c.4110-9C>G intronic variant is absent from the gnomAD v2.1.1 non-cancer dataset, in a position with adequate coverage (>20x) (PM2; http://gnomad.broadinstitute.org). It is predicted to cause the loss of the natural splicing acceptor of exon 28 but also a new splicing site is created/activated according to the 4 splicing predictors of the set SpliceSiteFinderlike-MaxEntScan-NNSplice-GeneSplicer (PP3). The variant was detected in an ataxia telangiectasia patient, together with the ATM c.362T>A (p.Leu121*) truncating variant (phase unknown), which awards it with 0.5 points as per ClinGen SVI Recommendation for in trans Criterion (PM3_Supporting; PMID: 21965147). According to the authors, the RNA analysis of the variant in the patient RNA found the predicted activation of a cryptic splice site leading to the insertion of the last 8 bp of intron 27, a frameshift and expectedly NMD (PS3_Supporting; PMID: 21965147). There is no other supporting data that meet criteria for consideration. Therefore, the clinical significance of this variant is uncertain. Adapted ACMG/AMP rules applied as defined by the Spanish ATM working group: PM2 + PP3 + PM3_Supporting + PS3_Supporting (PMID: 33280026).
Baylor Genetics RCV003476060 SCV004204468 likely pathogenic Familial cancer of breast 2023-10-23 criteria provided, single submitter clinical testing
Myriad Genetics, Inc. RCV003476060 SCV004932186 likely pathogenic Familial cancer of breast 2024-01-23 criteria provided, single submitter clinical testing This variant is considered likely pathogenic. This variant has been reported in multiple individuals with clinical features of gene-specific disease [PMID: 21965147]. This variant is expected to disrupt protein structure [Myriad internal data].

The information on this website is not intended for direct diagnostic use or medical decision-making without review by a genetics professional. Individuals should not change their health behavior solely on the basis of information contained on this website. Neither the University of Utah nor the National Institutes of Health independently verfies the submitted information. If you have questions about the information contained on this website, please see a health care professional.